Phase I/II sequencing study of azacitidine, epacadostat, and pembrolizumab in advanced solid tumors.
Jason John LukeMarwan FakihCharles SchneiderE Gabriela ChioreanJohanna BendellRebecca S KristeleitRazelle KurzrockSarah P BlagdenIrene BranaLaura W GoffKevin O'HayerRyan GeschwindtMichael SmithFeng ZhouAung NaingPublished in: British journal of cancer (2023)
Although the azacitidine-epacadostat-pembrolizumab regimen was well tolerated, it was not associated with substantial clinical response in patients with advanced solid tumors previously exposed to immunotherapy.